Peregrine Asset Advisers, Inc. Cytom X Therapeutics, Inc. Transaction History
Peregrine Asset Advisers, Inc.
- $243 Million
- Q1 2025
A detailed history of Peregrine Asset Advisers, Inc. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Peregrine Asset Advisers, Inc. holds 10,000 shares of CTMX stock, worth $7,700. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$7,700
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
70Shares Held
45.9MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$5.63 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.03 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$3.97 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$3.01 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$2.48 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $50.8M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...